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CONCLUSION: There is a substantial increase in the
management costs of AIDS in the last year of life.
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OBJECTIVE: To determine the cost impact of four sys-
temic regimens for the treatment of newly diagnosed cy-
tomegalovirus (CMV) retinitis in persons with AIDS. 
METHODS: An incidence-based simulation model was
developed to evaluate the economic implications of treat-
ing CMV retinitis from a government payer perspective.
The model randomly assigned patients to one of four sys-
temic treatment regimens for induction and maintenance
therapies: 1) ganciclovir IV/IV; 2) ganciclovir IV/PO; 3)
foscarnet IV/IV; and 4) cidofovir IV/IV. Following a sec-
ond relapse patients were randomly assigned an alterna-
tive therapy in order to assess the impact of various fail-
ure treatment strategies. Efficacy and safety data were
extracted from a systematic review of available literature
and publicly available sources. Resource use and cost
data were obtained from a large, AIDS treatment facility
in Switzerland. The primary outcome measures were time
to first and subsequent progression, duration of mainte-
nance treatment, and associated direct medical expendi-
tures (1998 Swiss francs). Nonmedical costs and quality
of life benefits were not considered. 
RESULTS: The median time to first progression was
greatest for cidofovir followed by foscarnet, ganciclovir
IV, and ganciclovir PO. The average 1-year costs in the
base case were lowest in patients initially randomized to
cidofovir (87,867 CHF) followed by randomization to
ganciclovir IV/PO (110,410 CHF), ganciclovir IV/IV
(117,406 CHF), and foscarnet IV/IV (120,662 CHF).
Sensitivity analyses of costs, effectiveness, and adverse
event rates resulted in changes in the cost estimates, how-
ever the order remained unchanged. 
CONCLUSIONS: Of the four treatment regimens stud-
ied, beginning treatment with systemic cidofovir is most
effective and least costly over a 1-year period.
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OBJECTIVES: AIDS treatment specialists advocate ag-
gressive (triple drug therapy) treatment of HIV/AIDS, but
limited research suggests that this position is not widely
held. Database studies are being used increasingly to pro-
vide information about patient behavior (e.g., identifica-
tion of treatment regimens and adherence with treatment
regimens). 
METHODS: A retrospective database study was con-
ducted to identify initial treatment regimens prescribed
for patients, changes in treatment regimens over time,
and patient adherence to their treatment regimens. 
RESULTS: Two patient cohorts were identified: one initi-
ating therapy after triple drug therapy was introduced and
before it was advocated as the treatment of choice; and
one initiating therapy after triple drug therapy was advo-
cated by HHS and the AMA. AIDS drugs prescriptions
filled for a 12-month period following initiation of therapy
were extracted from the database for each patient cohort. 
RESULTS: Findings indicate that 1) triple drug therapy is
not widely prescribed as an initiation therapy, 2) after
initiating therapy many patients must switch or augment
their treatment regimens, and 3) after 12 months of ther-
apy the triple drug regimen is still not widely prescribed. 
CONCLUSIONS: The results of this study provide further
evidence of the utility of retrospective database studies to
provide healthcare providers with cost-effective healthcare
delivery information.
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Data support the link between adherence to HIV treatment
and detectability of HIV RNA (a predictor of disease pro-
gression), making adherence a vital issue in HIV therapy. 
OBJECTIVE: To develop and assess a questionnaire to
measure adherence to HIV treatment. 
METHODS: Items from two existing measures, the Pa-
tient Medication Adherence Questionnaire (PMAQ) and
the Treatment Review and Satisfaction Questionnaire
(TRaSQ), were tested and revised using feedback from fo-
cus groups and in-depth interviews with 28 US and 29 Ital-
ian HIV-infected patients. This assessment highlighted is-
sues surrounding adherence, including patient beliefs,
knowledge and attitudes, lifestyle changes, medication
characteristics, regimen complexity, side effects, patient-
provider relationships, and patient recall. The subsequent
instrument, the PMAQ7, contains Likert-type items ad-
dressing these issues, and a behavioral assessment of ad-
herence over the past 7 days. 
RESULTS: Patients indicated that the PMAQ7 addressed
issues that were important to HIV patients, including side
effects and convenience of regimens. They added that an
issue’s importance could vary with the length of time that
a patient has been on HIV treatment. In addition, cultural
